Literature DB >> 1504750

Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan.

H Azuma1, Y Niimi, H Hamasaki.   

Abstract

1. The present experiments were designed to investigate the role of local angiotensin II receptors in the myointimal proliferative response of the vascular wall after endothelial removal, by use of a novel, nonpeptide, angiotensin II receptor antagonist, losartan. 2. When administered 1 week before endothelial removal from the rabbit carotid artery and then continuously until animals were killed 6 weeks later, losartan in a dose of 10 mg kg-1 daily, p.o. had no significant effects on the carotid blood flow (CBF), mean arterial blood pressure (MBP) and heart rate (HR). 3. A full endothelial lining with increased density of regenerated endothelial cells was observed 6 weeks after the endothelial removal. These changes were unaffected by treatment with losartan. 4. Six weeks after endothelial removal, acetylcholine (ACh)- and adenosine diphosphate (ADP)-induced relaxations were greatly reduced though endothelial cells had regenerated. The reduction of the relaxations to these agonists were significantly restored by chronic treatment with losartan. The endothelial-independent, sodium nitroprusside (SNP)-induced relaxation remained unaffected in all groups. 5. There were no differences in the noradrenaline (NA)- and endothelin-1 (ET-1)-induced contractions of the carotid artery strips between vehicle and losartan-treated groups. In contrast, the contractile response of the strips to angiotensin II was significantly decreased in the losartan group, indicating the specific antagonism by chronic losartan against the angiotensin II receptor. 6. Six weeks after endothelial removal, marked myointimal proliferation resulting from new accumulation of proliferating smooth muscle cells and connective tissue was observed in the vehicle group. Losartan treatment greatly suppressed the myointimal proliferative response.7. These results suggest that the local angiotensin II receptors play a role in the myointimal proliferativeresponse of the vascular wall to removal of the endothelium.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1504750      PMCID: PMC1907548          DOI: 10.1111/j.1476-5381.1992.tb14392.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Angiotensin-induced hypertension in the rat. Sympathetic nerve activity and prostaglandins.

Authors:  F C Luft; C S Wilcox; T Unger; R Kühn; G Demmert; P Rohmeiss; D Ganten; R B Sterzel
Journal:  Hypertension       Date:  1989-10       Impact factor: 10.190

2.  Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury.

Authors:  J S Powell; J P Clozel; R K Müller; H Kuhn; F Hefti; M Hosang; H R Baumgartner
Journal:  Science       Date:  1989-07-14       Impact factor: 47.728

3.  Endothelium-dependent inhibition of platelet aggregation.

Authors:  H Azuma; M Ishikawa; S Sekizaki
Journal:  Br J Pharmacol       Date:  1986-06       Impact factor: 8.739

4.  Alpha 1-adrenergic stimulation of platelet-derived growth factor A-chain gene expression in rat aorta.

Authors:  M W Majesky; M J Daemen; S M Schwartz
Journal:  J Biol Chem       Date:  1990-01-15       Impact factor: 5.157

Review 5.  Role of endothelium in responses of vascular smooth muscle.

Authors:  R F Furchgott
Journal:  Circ Res       Date:  1983-11       Impact factor: 17.367

6.  Endothelin is a potent mitogen for rat vascular smooth muscle cells.

Authors:  Y Hirata; Y Takagi; Y Fukuda; F Marumo
Journal:  Atherosclerosis       Date:  1989-08       Impact factor: 5.162

7.  The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

8.  Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.

Authors:  P C Wong; W A Price; A T Chiu; J V Duncia; D J Carini; R R Wexler; A L Johnson; P B Timmermans
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

9.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.

Authors:  R M Palmer; A G Ferrige; S Moncada
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

10.  Calcium-dependent contractile response of arterial smooth muscle to a jellyfish toxin (pCrTX: Carybdea rastonii).

Authors:  H Azuma; M Ishikawa; T Nakajima; A Satoh; S Sekizaki
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

View more
  8 in total

1.  Intimal hyperplasia in human uterine arteries accompanied by impaired synergism between prostaglandin I2 and nitric oxide.

Authors:  S Obayashi; T Aso; J Sato; H Hamasaki; H Azuma
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia.

Authors:  H Masuda; M Goto; S Tamaoki; H Azuma
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

3.  Induction of kinin B1 receptor-dependent vasoconstriction following balloon catheter injury to the rabbit carotid artery.

Authors:  D Pruneau; J M Luccarini; C Robert; P Bélichard
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

4.  Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury.

Authors:  E H Ohlstein; S A Douglas; C P Sung; T L Yue; C Louden; A Arleth; G Poste; R R Ruffolo; G Z Feuerstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

5.  Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells.

Authors:  H Azuma; J Sato; H Hamasaki; A Sugimoto; E Isotani; S Obayashi
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

6.  AT1 receptor characteristics of angiotensin analogue binding in human synovium.

Authors:  D A Walsh; T Suzuki; G A Knock; D R Blake; J M Polak; J Wharton
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

7.  Role of endothelium in the human uterine arteries during normal menstrual cycle.

Authors:  H Azuma; S Obayashi; H Hamasaki; T Koyama; T Aso
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

8.  Angiotensin II, a unique vasoactive agent dissociates myosin light chain phosphorylation from contraction.

Authors:  Takashi Hirano; Takeharu Kaneda; Hiroshi Ozaki; Masatoshi Hori
Journal:  J Vet Med Sci       Date:  2017-12-20       Impact factor: 1.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.